Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic.

Internal medicine journal - 1 Nov 2003

Kontorinis N, Garas G, Young J, Speers D, Chester B P, MacQuillan G C, De Boer B, Chapman M D, Forster E, Jeffrey G P

Abstract excerpt

BACKGROUND AND AIMS: To determine response rate, side-effects and compliance in patients with chronic hepatitis C virus (HCV) infection following treatment with interferon-alpha-2b and ribavirin in a 'shared care' hospital clinic. METHODS: Data were collected prospectively on 81 patients treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Patient Compliance

Share to Ribavirin

Source

Identifiers

PMID: 14656252
DOI: 10.1046/j.1445-5994.2003.00410.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-14656252-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic.PMID 14656252Read ↗

Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting.Semantic proximity Read ↗

Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.Semantic proximity Read ↗

[Outcome of treatment with peg-interferon and ribavirin in HIV-HCV co-infected patients: "real life" single center experience].Semantic proximity Read ↗

Delivery of treatment for hepatitis C virus infection in the primary care setting.Semantic proximity Read ↗

An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.Semantic proximity Read ↗

Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.Semantic proximity Read ↗

Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada).Semantic proximity Read ↗

A systematic review of community based hepatitis C treatment.Semantic proximity Read ↗

Hepatitis C antiviral treatment outcomes are comparable between clinical trial participants and recipients of standard-of-care therapy: an analysis of trial effect.Semantic proximity Read ↗

A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.Semantic proximity Read ↗

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.Semantic proximity Read ↗

Sustained virologic response to treatment in 100% of patients recently infected, nosocomially, with HCV genotype 2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.